Expert consensus on Shujin Jianyao Pills in clinical practice.
10.19540/j.cnki.cjcmm.20200218.501
- Author:
Huan LIU
1
;
Jing-Hua GAO
2
;
Yan-Ming XIE
1
;
Yuan-Yuan LI
1
;
Ling ZHANG
3
;
Sheng-Hua LI
4
;
Zu-Jian XU
5
;
Feng HUANG
6
;
Gang LI
7
;
Yong-Yan WANG
1
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.
3. Capital Medical University Beijing 100069, China.
4. Gansu Provincial Hospital of Traditional Chinese Medicine Lanzhou 730050,China.
5. Traditional Chinese Medicine Hospital Affiliated to South-east Medical University Luzhou 646000, China.
6. the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510405, China.
7. the Affiliated Hospital, Shandong University of Traditional Chinese Medicine Ji'nan 250014, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Shujin Jianyao Pills;
evidence-based medicine;
expert consensus;
traditional Chinese medicine
- MeSH:
Consensus;
Drugs, Chinese Herbal;
Humans;
Inflammation;
Medicine, Chinese Traditional;
Nonprescription Drugs
- From:
China Journal of Chinese Materia Medica
2020;45(10):2300-2303
- CountryChina
- Language:Chinese
-
Abstract:
Shujin Jianyao Pills is a Chinese patent medicine, with anti-inflammation, analgesic and anti-osteoporotic effects. Based on a questionnaire investigation of clinicians and a systematic review of study literatures on Shujin Jianyao Pills, the international clinical practice guidelines development method was adopted to analyze the optimal available evidences and expert experiences in the "evidence-based, consensus-based and experience-based" principles. Expert consensus on Shujin Jianyao Pills in clinical practice(GS/CACM267-2019) was developed by more than 30 multidisciplinary experts nationwide with the aim to guide and standardize the rational use of Shujin Jianyao Pills among clinicians and improve the clinical efficacy and safety. The expert consensus adopted the internationally recognized recommendation criteria for classification of evidence--GRADE. Expert consensus was formed by the nominal group method. Six main considerations were quality of evidence, curative effect, safety, economical efficiency, patient acceptability and other factors. If there were sufficient evidences, a "recommendation" was given, and GRADE grid voting rule was adopted. If there wasn't sufficient evidence, a "consensus opinion" was formed, and the majority counting rule. According to the indication, usage and do-sage, drug use for special population and safety of Shujin Jianyao Pills, one recommendation and nine consensus opinions were put forward. By means of expert meetings and correspondence, a nationwide consultations and peer reviews were conducted. This consensus is applicable to clinicians in hospitals and grass-roots health services, and provides guidance and reference for the rational use of Shujin Jianyao Pills.
